Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy.

Ann Surg Oncol

Service de Chirurgie Digestive et Oncologique, Assistance Publique des Hôpitaux de Paris, Hôpital Lariboisière, Paris, France.

Published: December 2017

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-017-6197-4DOI Listing

Publication Analysis

Top Keywords

cytoreductive surgery
4
surgery perioperative
4
perioperative intraperitoneal
4
intraperitoneal chemotherapy
4
cytoreductive
1
perioperative
1
intraperitoneal
1
chemotherapy
1

Similar Publications

Oncological Outcomes From Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy for Colorectal Cancer Peritoneal Metastases.

Clin Colorectal Cancer

December 2024

Colorectal and Peritoneal Oncology Centre (CPOC), The Christie NHS Foundation Trust, Manchester, United Kingdom; Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom. Electronic address:

Cytoreductive surgery (CRS) is effective for colorectal cancer peritoneal metastases (CRPM) at increasing overall survival (OS) compared to systemic anticancer treatment (SACT) alone. The addition of Oxaliplatin heated intraperitoneal chemotherapy (HIPEC) has been shown in a randomized controlled trial to result in increased complications without significant OS benefit. This study evaluates outcomes for CRPM patients undergoing CRS+HIPEC with Oxaliplatin (Ox) 368mg/m (30 min), versus Mitomycin C (MMC) 35mg/m (90min).

View Article and Find Full Text PDF

Objective: To provide up-to-date European Society of Urogenital Radiology (ESUR) guidelines for staging and follow-up of patients with ovarian cancer (OC).

Methods: Twenty-one experts, members of the female pelvis imaging ESUR subcommittee from 19 institutions, replied to 2 rounds of questionnaires regarding imaging techniques and structured reporting used for pre-treatment evaluation of OC patients. The results of the survey were presented to the other authors during the group's annual meeting.

View Article and Find Full Text PDF

Evolution in the Surgical Management of Gastric Cancer Peritoneal Metastases.

Cancers (Basel)

December 2024

Department of Surgery, Division of Surgical Oncology, NYU Langone Health, NYU Grossman Long Island School of Medicine, Mineola, NY 11501, USA.

Despite therapeutic treatments and the growing utilization of multimodal therapies, gastric cancer (GC) remains a highly aggressive malignancy with high mortality worldwide. Much of the complexity in treating GC is due to the high incidence of peritoneal metastasis (PM), with mean overall survival typically ranging from 4 to 10 months. With current systemic therapy, targeted therapies, and immunotherapies continuing to remain ineffective for GC/PM, there has been a significant growing interest in intraperitoneal (IP) therapies for the treatment of GC/PM.

View Article and Find Full Text PDF

Rationale: Peritoneal mucinous cystadenoma is rare in the clinic, lacks specific clinical manifestations, tumor markers, and imaging features, and is easily misdiagnosed and missed. Clinical practitioners should maintain a high level of vigilance. Here, we report a case of laparoscopic peritoneal mucinous cystadenoma stripping to improve our understanding of the disease.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!